Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-18T04:30:49.558Z Has data issue: false hasContentIssue false
  • English
  • Français

A Six-Month Phosphatidylcholine Trial in Friedreich’s Ataxia

Published online by Cambridge University Press:  18 September 2015

A. Filla  and
G. Campanella
A. Filla
Affiliation:
Department of Neurology, Second School of Medicine, University of Naples, Italy
G. Campanella
Affiliation:
Department of Neurology, Second School of Medicine, University of Naples, Italy
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In a six-month open pilot study, pure phosphatidylcholine was administered intravenously (2.5g daily for a month) and orally (5g daily for five months) to sixteen patients with Friedreich’s ataxia (FA) and seven patients with other inherited ataxias. Only the oral treatment achieved a mild but significant, 25% improvement, mainly of “central” symptoms in the FA patients at stage 2 of the illness, that is, still able to walk without support and to lead an independent life. However, the drug was ineffective in the more advanced cases. These results are discussed and compared with those obtained with lecithin by other authors.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 9 , Issue 2 , May 1982 , pp. 147 - 150
Copyright
Copyright © Canadian Neurological Sciences Federation 1982

References

REFERENCES

Barbeau, A. (1978a). Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can. J. Neurol. Sci. 5, 157–160.CrossRefGoogle ScholarPubMed
Barbeau, A. (1978b). Phosphatidylcholine (lecithin) in neurological disorders. Neurology 25, 358.Google Scholar
Barbeau, A. (1978c). Lecithin in neurological disorders. N. Engl. J. Med. 229, 200–201.Google Scholar
Barbeau, A. (1979). Lecithin in movement disorders. Nutrition and the Brain, eds. Barbeau, A., Growdon, J.H. & Wurtman, R.J., pp. 263–271. Raven Press, New York.Google Scholar
Campanella, G., Filla, A., De Falco, F., Mansi, D., Durivage, A. and Barbeau, A. (1980). Friedreich’s ataxia in the South of Italy. A clinical and biochemical survey of 23 patients. Can. J. Neurol. Sci. 7, 351–357.CrossRefGoogle ScholarPubMed
Caruso, G., Santoro, L., Perretti, A., Barbieri, F., Serlenga, L., and Filla, A. (1981). Friedreich’s ataxia: an electrophysiological and byoptical study. Submitted to Brain.Google Scholar
Chamberlain, S., Robinson, N., Walker, J., Smith, C., Benton, S., Kennard, C., Swash, M., Kilkenny, B., and Bradbury, S. (1980). Effect of lecithin on disability and plasma free-choline levels in Friedreich’s ataxia. J. Neurol, Neurosurg. Psych. 43, 843–845.CrossRefGoogle ScholarPubMed
Davignon, J., Huang, Y.S., Wolf, J.P. and Barbeau, A. (1979). Fatty acid profile of major lipid classes in plasma lipoproteins of patients with Friedreich’s ataxia. Demonstration of a low linoleic acid content most evident in the cholesterylester fraction. Can. J. Neurol. Sci. 6, 275–284.CrossRefGoogle ScholarPubMed
Filla, A., Carlomangno, S., Di Iorio, G., Federico, A., Guadagnino, M. and Campanella, G. (1979). Studio epidemiologico delle eredoatassie spino-cerebellari in Campania. Atti della 6” Riunione L.I.M.P.E., 23–31.Google Scholar
Geoffroy, G., Barbeau, A., Breton, G., Lemieux, B., Aube, M., Leger, C. and Bouchard, J.B. (1976). Clinical description and roentgenologic evaluation of patients with Friedreich’s ataxia. Can. J. Neurol. Sci. J, 279–286.CrossRefGoogle ScholarPubMed
Giovannino, P., Ladinski, H., Consolo, S., Parati, E., Caraceni, F. (1979). La lecitina nel trattamento delle sindromi atassiche. Atti della 6a iunione L.I.M.P.E., 65–74.Google Scholar
Gudmundsson, K.R. (1969). Prevalence and occurrence of some rare neurological diseases in Iceland. Acta Neurol. Scand. 45, 114–118.Google ScholarPubMed
Lawrence, CM., Millac, P., Stout, G.S. and Ward, J.W. (1980). The use of choline chloride in ataxic disorders. J. Neurol. Neurosurg. Psych. 43, 452–454.CrossRefGoogle ScholarPubMed
Legg, N.J. (1978). Oral choline in cerebellar ataxia. Br. Med. J. 2, 1403–1404.CrossRefGoogle ScholarPubMed
Livingstone, I.R., Mastaglia, F.L. (1979). Choline chloride in the treatment of ataxia. Br. Med. J. ii, 939.CrossRefGoogle Scholar
Philcox, D.V., Kies, B. (1979). Choline in hereditary ataxia. Br. Med. J. ii, 613.CrossRefGoogle Scholar
Reynolds, S.F., Blass, J.P. (1976). A possible mechanism for selective cerebellar damage in partial pyruvate dehydrogenase deficiency. Neurology 26, 625–628.CrossRefGoogle ScholarPubMed
Rodriguez-Budelli, M.M., Kark, R.A.P., Blass, I.P., and Spence, M.A. (1978). Action of physostigmine on inherited ataxias. Advances in Neurology, vol. 21, eds. Kark, R.A.P., Rosenberg, R.N. and Schut, L.J., pp. 195–202. Raven Press, New York.Google Scholar
Sehested, P., Lund, H.I., and Kristensen, O. (1980). Oral choline in cerebellar ataxia. Acta Neurol. Scand. 62, 124–126.CrossRefGoogle ScholarPubMed
Skre, H. (1975). Friedreich’s ataxia in Western Norway. Cli. Gen. 7, 265–288.Google ScholarPubMed